Abstract
Backgroud: Tsutsugamushi disease was really uncommon in the pediatric clinical. However, it can be quite severe, those who suffer them Tsutsugamushi disease can progress to multiple organ dysfunction syndrome (MODS) and hemophagocytic syndrome (HPS). Unfortunately, there were few reports on pulmonary hemorrhage caused by tsutsugamushi disease, especially in children. Because of the nonspecific clinical presentations, it was difficult to differentiate from other diseases. The mortality would be up to 60% if inappropriate antibiotics were used.
Case Presentation: We report a three-year-old girl infected with tsutsugamushi, which manifested as MODS, HPS and diffuse alveolar hemorrhage. After administation of chloromycetin, the patient’s temperature fell down to normal 2 days later and mechanical ventilation was stopped after 1 week. The patient was discharged after three weeks of treatment. Since the typical eschar of tsutsugamushi disease is mostly concealed, misdiagnosis and delay in treatment often cause severe complications.
Conclusion: Chloromycetin may be an alternative antibiotic choice of treatment for severe pediatric tsutsugamushi disease, though it has toxic effects on bone marrow hematopoietic function.
Keywords: Chloromycetin, pediatric, pulmonary hemorrhage, tsutsugamushi.
Current Signal Transduction Therapy
Title:Successful Treatment of Pulmonary Hemorrhage Associated with Pediatric Tsutsugamushi Disease by Chloromycetin
Volume: 10 Issue: 1
Author(s): Yafeng Liang, Linxia Wang, Xiaojiao Ye, Min Wang, Chunxue Yan and Guoquan Pan
Affiliation:
Keywords: Chloromycetin, pediatric, pulmonary hemorrhage, tsutsugamushi.
Abstract: Backgroud: Tsutsugamushi disease was really uncommon in the pediatric clinical. However, it can be quite severe, those who suffer them Tsutsugamushi disease can progress to multiple organ dysfunction syndrome (MODS) and hemophagocytic syndrome (HPS). Unfortunately, there were few reports on pulmonary hemorrhage caused by tsutsugamushi disease, especially in children. Because of the nonspecific clinical presentations, it was difficult to differentiate from other diseases. The mortality would be up to 60% if inappropriate antibiotics were used.
Case Presentation: We report a three-year-old girl infected with tsutsugamushi, which manifested as MODS, HPS and diffuse alveolar hemorrhage. After administation of chloromycetin, the patient’s temperature fell down to normal 2 days later and mechanical ventilation was stopped after 1 week. The patient was discharged after three weeks of treatment. Since the typical eschar of tsutsugamushi disease is mostly concealed, misdiagnosis and delay in treatment often cause severe complications.
Conclusion: Chloromycetin may be an alternative antibiotic choice of treatment for severe pediatric tsutsugamushi disease, though it has toxic effects on bone marrow hematopoietic function.
Export Options
About this article
Cite this article as:
Liang Yafeng, Wang Linxia, Ye Xiaojiao, Wang Min, Yan Chunxue and Pan Guoquan, Successful Treatment of Pulmonary Hemorrhage Associated with Pediatric Tsutsugamushi Disease by Chloromycetin, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150311001316
DOI https://dx.doi.org/10.2174/1574362410666150311001316 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial:
Current Immunology Reviews (Discontinued) Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews A New Biomarker with High Outcome Prediction in IgA Nephropathy
Recent Patents on Biomarkers Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology The Immunosuppressive Agent FK506 Prevents Subperineurial Degeneration and Demyelination on Ultrastructural and Functional Analysis
Current Neurovascular Research Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Anesthetic Cardioprotection: The Role of Adenosine
Current Pharmaceutical Design Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Drug Targets in Infections with Ebola and Marburg Viruses
Infectious Disorders - Drug Targets Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews An Update on the Cardiovascular Effects of Quercetin, a Plant Flavonoid
Current Nutrition & Food Science Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Regulation of Platelet Function by Acetylation/Deacetylation Mechanisms
Current Medicinal Chemistry Type I Interferon as a Target of Treatment in SLE
Endocrine, Metabolic & Immune Disorders - Drug Targets The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews